Cue Biopharma (CUE) Fundamental Analysis: Revenue, Earnings & Valuation

5.45 / 10

Netural

Fundamentally, Cue rates Neutral with a 5.5/10 score. Revenue‑MV, Cash‑MV and PB‑ROE are strong, but Fixed‑assets turnover and Income‑tax‑to‑profit ratios lag. Overall, modest financial health with some efficiency concerns.

Analysis Checks(7/10)

Revenue-MV

Value1.49

Score2/3

Weight22.05%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value195.75

Score2/3

Weight-2.17%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.97%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight4.10%

1M Return1.69%

PB-ROE

Value-0.62

Score3/3

Weight28.19%

1M Return9.74%

Income tax / Total profit (%)

Value-1.92

Score1/3

Weight-1.04%

1M Return-0.50%

Fixed assets turnover ratio

Value6.00

Score1/3

Weight-2.51%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.39%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight7.06%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight15.96%

1M Return5.94%

Is CUE undervalued or overvalued?

CUE scores 5.45/10 on fundamentals and holds a Fair valuation at present. Backed by its -121.11% ROE, -96.85% net margin, -0.88 P/E ratio, 0.88 P/B ratio, and 61.11% earnings growth, these metrics solidify its Netural investment rating.